Compare Quest Diagnostics Inc (DGX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $237.69 (market cap $26.21B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.16. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | TLT | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | — |
52-Week High | $238.50 | $92.06 |
52-Week Low | $173.49 | $82.05 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.29 with a slight 0.3% daily gain amid bearish technical signals. The ETF faces pressure from rising long-term Treasury yields, with the 30-year yield recently hitting 5.24% (The Motley Fool, 2026-08-02). Institutional interest persists as Ferguson Shapiro LLC acquired 37,900 shares (Defense World, 2026-08-10), but outflows and U.S. debt nearing $40 trillion weigh on sentiment.
Outlook remains cautious as higher yields and inflation concerns challenge TLT's performance. Opportunities exist for income-focused investors given dividend payments, but risks include Fed rate hike potential and escalating geopolitical tensions driving oil prices higher. The bearish technical setup suggests continued pressure unless bond market sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
